Kotobuki Realty

Kotobuki Realty is a Japanese private holding company that serves as the primary corporate vehicle for the Takehana family's life science and pharmaceutical interests. The company is the parent entity of Kotobuki Pharmaceutical, a research-driven firm established in 1949 that focuses on small molecule drug discovery and manufacturing. It also holds a significant stake in KOTAI Biotechnologies, a specialized unit utilizing artificial intelligence and high-throughput sequencing for immune repertoire analysis. Through its subsidiaries, Kotobuki Realty has successfully brought products to market, most notably the SGLT2 inhibitor ipragliflozin for the treatment of type 2 diabetes. The organization maintains a vertically integrated approach, overseeing everything from early-stage computational discovery to late-stage clinical development and GMP manufacturing. Based in Saitama, Japan, Kotobuki Realty continues to expand its portfolio through internal R&D and strategic investments in cutting-edge biotechnological platforms.